What is the difference between AI tools for medcomms and general AI writing tools?

Anthony Stackman ·

AI tools built specifically for medical communications can do things that general AI writing tools fundamentally cannot: they understand regulatory frameworks, apply clinical accuracy standards, and produce content that holds up under scientific and compliance scrutiny. General AI tools are trained to produce fluent, persuasive prose — but fluency is not the same as accuracy, and in medcomms, the gap between the two carries real professional and regulatory risk. The questions below unpack where that gap matters most and how pharma and biotech teams should think about their AI choices in 2026.

What can AI tools built for medcomms do that general AI can’t?

Medcomms-specific AI tools are designed to handle scientific source referencing, regulatory language requirements, and clinical terminology with a level of precision that general AI writing tools are not built to deliver. They can cross-reference claims against source documents, flag language that may fall outside ABPI, FDA, or EMA guidance, and maintain the structured, evidence-anchored writing style that medical affairs and regulatory teams expect.

General AI tools — including the most capable large language models available today — are optimised for coherence and readability. They produce text that sounds authoritative. But in medical communications, sounding authoritative and being clinically accurate are entirely different standards. A general AI tool has no mechanism to distinguish between a claim that is well-supported in the literature and one that is plausible but unverified. Medcomms-specific tools are built with that distinction at their core.

Beyond accuracy, specialist AI tools for medical communications are typically designed to support structured workflows: integrating with reference management systems, flagging data gaps for medical writer review, and producing outputs that align with submission-ready or congress-ready formats. These are operational capabilities that general writing tools do not offer.

How does training data affect accuracy in medical content?

Training data is the single most important factor separating reliable medical AI tools from general AI writing tools. A general AI model trained on broad internet text will have absorbed a vast mixture of accurate, outdated, speculative, and occasionally incorrect medical information. It cannot reliably distinguish between a peer-reviewed meta-analysis and a health blog, because its training did not require it to.

AI tools developed for medical communications are trained on curated, domain-specific datasets: clinical literature, regulatory guidance documents, prescribing information, and validated medical writing outputs. The model’s baseline understanding of terminology, evidence hierarchies, and appropriate claim structures is therefore calibrated to the standards of the field rather than to general readability.

The practical consequence is significant. When a general AI tool writes about a mechanism of action, a clinical endpoint, or a patient population, it produces text that may be broadly correct but lacks the precision required for medical affairs materials, payer submissions, or HCP-facing content. In medcomms, imprecision is not a stylistic issue — it is a compliance and credibility issue.

Which types of medcomms content are too risky for general AI tools?

Several categories of medcomms content carry enough regulatory and scientific risk that using general AI writing tools without rigorous expert oversight is not advisable. These include promotional materials for prescription medicines, payer value dossiers, medical information responses, clinical trial communications, and any content that makes direct or implied efficacy or safety claims.

The risk in each case is similar: general AI tools generate text based on pattern recognition, not verified scientific reasoning. A value dossier that misrepresents clinical data — even subtly — can undermine a market access submission. Promotional copy that implies a benefit not supported by the approved label creates regulatory exposure. Medical information responses that blend accurate data with plausible-sounding but unsupported claims can reach patients or healthcare professionals and cause genuine harm.

Lower-stakes content — internal briefing documents, background landscape summaries, early-stage ideation — carries less risk when general AI tools are involved, provided outputs are reviewed by qualified medical writers before any external use. The key variable is always whether the content will be seen by HCPs, patients, payers, or regulators, and whether claims within it will be treated as authoritative.

What role does human oversight play when using AI in medcomms?

Human oversight is not optional in medical communications AI workflows — it is the mechanism that makes AI-generated content usable. Regardless of how capable a medcomms AI tool is, qualified medical writers, medical affairs professionals, and regulatory reviewers remain responsible for the accuracy, appropriateness, and compliance of any content that carries scientific or clinical weight.

AI tools, even specialist ones, can hallucinate references, misapply clinical context, or produce language that is technically accurate but strategically inappropriate for a given audience or regulatory environment. Human reviewers catch these errors. They also bring contextual judgement that no AI tool currently replicates: understanding what a particular payer needs to hear, how a specific HCP audience will interpret a claim, or how a piece of content fits within a broader medical strategy.

The most effective medcomms AI workflows treat AI as a drafting and efficiency tool, not a decision-maker. AI compresses the time required to produce a first draft, structure a literature summary, or generate multiple content variants. Experienced medical communicators then apply the scientific, strategic, and regulatory judgement that determines whether any of those drafts are fit for purpose.

Should pharma and biotech teams use general AI tools for any medcomms tasks?

General AI writing tools have a legitimate but limited role in medcomms workflows. They are most useful for tasks where scientific accuracy is not the primary concern and where outputs will always be reviewed before use — brainstorming content structures, generating plain-language drafts for internal review, summarising background reading, or producing early-stage creative concepts for discussion.

Where general AI tools should not be the primary production tool is anywhere that scientific accuracy, regulatory compliance, or clinical precision is non-negotiable. For those tasks, the choice is between medcomms-specific AI tools used under expert oversight and experienced medical writers working without AI assistance. Both are defensible. Relying on a general AI tool and assuming the output is accurate is not.

Data governance is a further consideration. General AI platforms with cloud-based processing may not meet the data security requirements for unpublished clinical data, proprietary compound information, or patient-related content. Medcomms-specific tools are more likely to offer the enterprise-grade data handling that regulated industries require.

The practical guidance is straightforward: use general AI where it saves time on low-risk tasks, use specialist tools where accuracy and compliance matter, and ensure qualified humans review every output before it reaches an external audience.

How Wizzard approaches AI in medical communications

We work with pharmaceutical companies, biotech teams, and healthcare organisations to produce medical communications that are scientifically grounded and creatively distinctive. Our approach to AI reflects the same standards we apply across all our work: expert-led, evidence-anchored, and built for the specific regulatory and audience context of each project.

  • Medical writers and strategists lead every project, with AI used as a production tool rather than a content authority
  • All outputs are reviewed against source data, regulatory frameworks, and client governance requirements before use
  • We apply our consumer advertising expertise to produce medcomms that are bigger, brighter, and braver than clients expect, without compromising scientific integrity
  • Our work spans medical affairs, market access, patient engagement, payer communications, and educational programmes across UK, US, and EMEA markets

If your team is working out how to bring AI into medical communications workflows without introducing scientific or regulatory risk, we would welcome the conversation. Get in touch with Wizzard to discuss how we can support your medcomms strategy.

Related Articles